Histowiz

Histowiz is a histopathology company that develops assays and digitizes histology slides. The company has an annotated Whole Slide Imaging repository for histopathology data for collaboration and bioinformatics-driven discovery. Histowiz’s mission is to fight cancer and the company also developed assays for COVID-19 respiratory disease caused by SARS-CoV-2.

Histowiz provides specimen processing and staining of slides which are provided to customers in digital format as well as options for pathology consultation. PathologyMap is a platform for viewing, searching, tagging, collaboration, analysis and storage of pathology data and crowdsourcing from the biomedical research community. Data includes human and model organisms such as zebrafish, patient-derived xenografts and organoids. HistoWiz is developing machine learning tools for automatic tumor identification, mitosis count and image similarity search.

For COVID-19, Histowiz developed an automated immunohistochemistry assay to detect SARS-CoV2 nucleocapsid protein and in-situ hybridization assay using RNAscope technology to detect SARS-CoV2 RNA in a variety of COVID19 autopsy and biopsy tissues (e.g. lung, liver, kidney, spleen, heart, brain).

Founder and CEO, Ke Cheng has expertise in cancer research and mouse histopathology. She received her PhD from Harvard Medical School in the laboratory of Pier Paolo Pandolfi, was a Teaching Fellow at Harvard University, a postdoctoral fellow in the laboratory of Douglas Hanahan at ISREC and a scientist at the cancer diagnostic company Cancer Genetics (CGIX).